Diagnostic and prognostic value of presepsin in the management of sepsis in the emergency department: a multicenter prospective study

[1]  P. Mangin,et al.  Diagnostic value of soluble CD14 subtype (sCD14-ST) presepsin for the postmortem diagnosis of sepsis-related fatalities , 2013, International Journal of Legal Medicine.

[2]  C. Sprung,et al.  Surviving Sepsis Campaign: International Guidelines for Management of Severe Sepsis and Septic Shock, 2012 , 2013, Intensive Care Medicine.

[3]  M. Mussap,et al.  Soluble CD14 subtype (sCD14-ST) presepsin in critically ill preterm newborns: preliminary reference ranges , 2012, The journal of maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians.

[4]  H. Ishikura,et al.  Usefulness of presepsin in the diagnosis of sepsis in a multicenter prospective study , 2012, Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy.

[5]  M. Mussap,et al.  Soluble CD14 subtype presepsin (sCD14-ST) and lipopolysaccharide binding protein (LBP) in neonatal sepsis: new clinical and analytical perspectives for two old biomarkers , 2011, The journal of maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians.

[6]  D. Heyland,et al.  Procalcitonin for reduced antibiotic exposure in the critical care setting: A systematic review and an economic evaluation* , 2011, Critical care medicine.

[7]  Tomohiro Takahashi,et al.  Presepsin (sCD14-ST): development and evaluation of one-step ELISA with a new standard that is similar to the form of presepsin in septic patients , 2011, Clinical chemistry and laboratory medicine.

[8]  T. Ahrens,et al.  Improving outcomes for severe sepsis and septic shock: tools for early identification of at-risk patients and treatment protocol implementation. , 2008, Critical care clinics.

[9]  J. Bertrand,et al.  Can emergency physicians identify a high mortality subgroup of patients with sepsis: role of procalcitonin , 2008, European journal of emergency medicine : official journal of the European Society for Emergency Medicine.

[10]  J. Sunderram,et al.  Rapid increase in hospitalization and mortality rates for severe sepsis in the United States: A trend analysis from 1993 to 2003* , 2007, Critical care medicine.

[11]  J. Finn,et al.  Comparison of Acute Physiology and Chronic Health Evaluation (APACHE) II score with organ failure scores to predict hospital mortality , 2007, Anaesthesia.

[12]  Anthony S McLean,et al.  Accuracy of procalcitonin for sepsis diagnosis in critically ill patients: systematic review and meta-analysis. , 2007, The Lancet. Infectious diseases.

[13]  Derek C Angus,et al.  Severe sepsis epidemiology: sampling, selection, and society , 2004, Critical care.

[14]  D. Mannino,et al.  The epidemiology of sepsis in the United States from 1979 through 2000. , 2003, The New England journal of medicine.

[15]  R. Dellinger,et al.  Cardiovascular management of septic shock. , 2003, Critical care medicine.

[16]  E. Ivers,et al.  Early Goal-Directed Therapy in the Treatment of Severe Sepsis and Septic Shock , 2001 .

[17]  G. Clermont,et al.  Epidemiology of severe sepsis in the United States: Analysis of incidence, outcome, and associated costs of care , 2001, Critical care medicine.

[18]  J. Vincent,et al.  The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction/failure , 1996, Intensive Care Medicine.

[19]  G. Camussi,et al.  Lipopolysaccharide binding protein and CD14 modulate the synthesis of platelet-activating factor by human monocytes and mesangial and endothelial cells stimulated with lipopolysaccharide. , 1995, Journal of immunology.

[20]  I. L. Cohen.  Guidelines for the use of innovative therapies in sepsis. , 1993, Critical care medicine.

[21]  W. Knaus,et al.  Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. , 1992, Chest.

[22]  G. Takahashi,et al.  Usefulness of presepsin (sCD14-ST) measurements as a marker for the diagnosis and severity of sepsis that satisfied diagnostic criteria of systemic inflammatory response syndrome , 2011, Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy.

[23]  G. Takahashi,et al.  Evaluation of a newly identified soluble CD14 subtype as a marker for sepsis , 2005, Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy.